{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-004415","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.881585+00:00","generated_at":"2026-06-01T02:50:14.964679+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenetic appoints Parslow Interim CEO at $400k salary, $100k retention bonus; separations with former CEO/CSO","bullets":["James Parslow appointed Interim CEO effective May 16, 2024; base salary increased to $400,000.","Parslow eligible for $100,000 cash retention bonus if employed for ten months; receives option for 20,000 shares.","Confidential separation agreements with former CEO Jeffrey Eisenberg and former CSO Curtis Lockshin providing severance per existing agreements.","Eisenberg Separation Agreement includes accelerated vesting of all unvested stock options as of May 16, 2024.","Stock option grant vests 1/4 on grant date and 1/4 on each of first three anniversaries, subject to continued employment."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-004415","json":"https://secwatch.observer/filing/0001683168-24-004415.json","markdown":"https://secwatch.observer/filing/0001683168-24-004415.md","text":"https://secwatch.observer/filing/0001683168-24-004415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:50:14.964679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fcbdb1c1e","claim":"Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..","evidence_excerpt":"and Curtis Lockshin, the Company’s former Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"3fcad04398","claim":"Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..","evidence_excerpt":"the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e19044ef72","claim":"James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..","evidence_excerpt":"the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}